ANKRD22 Inhibitors
ANKRD22 inhibitors represent a class of chemical compounds designed to target the ANKRD22 protein, which contains ankyrin repeat domains crucial for facilitating protein-protein interactions. ANKRD22 belongs to the family of ankyrin repeat domain-containing proteins, which are known for their ability to act as scaffolding units that organize and stabilize multi-protein complexes. The ankyrin repeat domains within ANKRD22 consist of multiple helical structures that create a surface suitable for binding to other proteins, enabling ANKRD22 to play a key role in cellular signaling pathways, regulation of gene expression, and structural organization within the cell. ANKRD22 inhibitors are designed to specifically interfere with these interactions, preventing the protein from assembling or maintaining the complexes it is involved in, thereby affecting the function of the associated cellular mechanisms.
Chemically, ANKRD22 inhibitors vary in their structures, ranging from small molecules that can easily diffuse through cellular membranes to larger peptides or protein-based inhibitors designed to interact with the ankyrin repeat domains. These inhibitors often function by occupying or blocking the binding sites within the ankyrin repeat arrays, disrupting the natural ability of ANKRD22 to bind to its protein partners. Some inhibitors may mimic the structural motifs of the natural ligands of ANKRD22, effectively competing for binding in a manner that prevents the proper assembly of protein complexes. Alternatively, some inhibitors work by inducing conformational changes in the ANKRD22 protein, destabilizing the integrity of the ankyrin repeat domains and reducing their ability to participate in protein interactions. ANKRD22 inhibitors are useful tools in studying the molecular mechanisms that rely on ANKRD22's interactions, shedding light on its role in cellular architecture and regulatory processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. ANKRD22's function is regulated by phosphorylation; hence, inhibiting kinases that phosphorylate ANKRD22 will reduce its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src-family kinase inhibitor. ANKRD22 is involved in signaling pathways where Src kinases may play a role in phosphorylation events that regulate ANKRD22's activity, thus Dasatinib inhibition of these kinases can result in decreased function of ANKRD22. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an inhibitor of phosphoinositide 3-kinases (PI3K). If ANKRD22 is downstream of PI3K signaling, inhibiting PI3K can lead to a decrease in ANKRD22 activity by reducing activation signals. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, functioning similarly to Wortmannin, potentially leading to reduced activity of ANKRD22 by inhibiting upstream signaling pathways that regulate ANKRD22. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK signaling pathway. If ANKRD22 activity is influenced by ERK-mediated signaling, then PD98059 can reduce ANKRD22 activity by blocking this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor that can lead to decreased activation of ERK. Since ERK can modulate various proteins, inhibiting MEK with U0126 may lead to functional inhibition of ANKRD22 by reducing its phosphorylation state. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Inhibition of p38 MAPK can decrease ANKRD22 activity if ANKRD22 is regulated by stress-activated protein kinase signaling pathways, which involve p38 MAPK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK signaling pathway. By inhibiting JNK, SP600125 can decrease the activity of ANKRD22 if JNK signaling plays a role in regulating ANKRD22. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö6976 is an inhibitor of classical protein kinase C isoforms. If ANKRD22 activity is regulated by PKC-mediated phosphorylation, then Gö6976 can lead to functional inhibition of ANKRD22. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is another PKC inhibitor. By inhibiting PKC, which may be involved in the phosphorylation and activation of ANKRD22, chelerythrine can lead to a decrease in ANKRD22 activity. | ||||||